GSK 3437949A
Alternative Names: GSK-3437949; GSK-3437949ALatest Information Update: 27 Jul 2022
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Malaria vaccines; Recombinant proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Malaria
Most Recent Events
- 27 Jul 2022 Phase-II development is ongoing in Malaria prevention in United Kingdom (Parenteral) (GSK pipeline, July 2022)
- 26 Mar 2020 Phase-II clinical trials in Malaria prevention in United Kingdom (Parenteral) before March 2020 (GSK pipeline March 2020)